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Abstract 31 
Objectives: Overprescribing of antibiotics by general practitioners is seen as a major driver of 32 
antibiotic resistance. Training in communication skills and C-reactive protein (CRP) testing 33 
both appear effective in reducing such prescribing. This study assesses the cost-effectiveness 34 
of (i) training general practitioners (GPs) in the use of CRP testing, (ii) training GPs in 35 
communication skills and (iii) training GPs in both CRP testing and communication skills 36 
compared to usual care.    37 
Methods: Economic analyses (cost-utility analysis (CUA) accounting for the cost of antibiotic 38 
resistance and cost-effectiveness analysis (CEA)) were both conducted from a health care 39 
perspective with a time horizon of 28 days alongside a multinational, cluster, randomised, 40 
factorial controlled trial in patients with respiratory tract infections in five European countries. 41 
The primary outcome measures were QALYs and percentage reductions in antibiotic 42 
prescribing. Hierarchical modelling was used to estimate an incremental cost-per-QALY-43 
gained and an incremental cost-per-percentage-reduction in antibiotic prescribing. 44 
Results: Overall, the results of both the CUA and CEA showed that training in communication 45 
skills is the most cost-effective. However, excluding the cost of antibiotic resistance in the 46 
CUA resulted in usual care being the most cost-effective option. Country-specific results from 47 
the CUA showed that training in communication skills was cost-effective in Belgium, UK and 48 
Netherlands whilst training in CRP was cost-effective in Poland.  49 
Conclusion: Internet-based training in communication skills is a cost-effective intervention to 50 
reduce antibiotic prescribing for respiratory tract infections in primary care if the cost of 51 
antibiotic resistance is accounted for.    52 
  53 
Introduction 54 
Antibiotic resistance is currently one of the world’s leading public health concerns, which 55 
places a heavy burden on scarce resources. In the UK, resistant infections such as MRSA are 56 
estimated to cost the National Health Service an additional £1 billion in extra treatments 57 
annually1 and without a resolution ‘superbugs’ are estimated to cause more deaths than cancer 58 
by 2050, costing about $100 trillion globally.2 59 
The difficulty in determining who will benefit from prescribing, and desire to satisfy patients 60 
demands, appear to be driving inappropriate and over-prescribing of antibiotics by general 61 
practitioners (GPs).3-5 As well as impacting upon the development of resistance, antibiotic 62 
prescribing is associated with significant costs.6 The National Health Service in the UK incurs 63 
an annual cost of between $35(£23) and $70(£47) million in antibiotic prescription costs for 64 
acute cough/lower respiratory tract infections alone for example.7 Reducing the inappropriate 65 
and over-prescribing of antibiotics would thus not only help reduce the problem of antibiotic 66 
resistance but also save scarce resources. 67 
The rate of development of new antibiotics has slowed down over the past three decades8-11 68 
and the antibiotics currently available must be conserved. One way to assist with this protection 69 
is to find cost-effective ways of changing prescribing behaviour of GPs.  70 
Interventions to reduce prescribing, based on persuasion, have generally been ineffective in 71 
dealing with the problem12-13, and so more recent focus has turned to training GPs in advanced 72 
consulting skills and using point of care tests. These have resulted in a change in their 73 
prescribing behaviour,14,15 with internet-based training programmes providing a reduction in 74 
antibiotic prescribing similar to the standardized methods of training.16 Such internet-based 75 
training was developed by the Genomics to combat Resistance against Antibiotics in 76 
Community-acquired LRTI in Europe (GRACE) consortium.4,17-18 The interventions consisted 77 
of (i) training GPs in the use of C-reactive protein testing (‘CRP’), (ii) training GPs in 78 
communication skills (‘communication skills’) and (iii) training GPs in both CRP testing and 79 
communication skills (‘combined’).  80 
Results from the GRACE INTRO trial indicates that all three of these interventions (i) CRP 81 
(ii) communication skills and (iii) combined are effective in changing GP antibiotic prescribing 82 
behaviour.19 However, in addition to the effectiveness of these interventions, it is important to 83 
determine whether the interventions provide value for money. One study conducted a cost-84 
effectiveness analysis using reductions in antibiotic prescribing as an outcome measure and 85 
found all three interventions to be cost-effective compared with usual care.20 However, no 86 
study has assessed the cost-effectiveness of these interventions in a multinational setting or 87 
estimated the country-specific cost-effectiveness of these interventions. The aim of this study 88 
is to assess the cost-effectiveness of these interventions across five European countries.   89 
 90 
Patients and methods 91 
Patients and settings 92 
The economic analysis was conducted alongside a multinational, cluster, randomised, factorial 93 
controlled trial in which participating practices were randomised to one of four study groups 94 
(i) CRP, (ii) communication skills, (iii) combined and (iv) usual care.19 The perspective 95 
adopted was that of the health service, including costs to the health service and health care cost 96 
to the patient. Consenting participants who presented with respiratory tract infections were 97 
recruited from primary care networks across five countries in Europe: Belgium, Netherlands, 98 
Poland, Spain, and the United Kingdom (England and Wales). The study was approved by 99 
ethics committees in all countries and all eligible individuals provided written consent before 100 
participating in the study. Full details of the clinical trial and intervention have been published 101 
elsewhere.4,17-19  102 
 103 
Data collection 104 
Resource use 105 
The main sources of resource use information were the case report form (CRF) completed by 106 
primary care clinicians at the day of the consultation (day 1), and a diary completed by patients 107 
over a four-week period starting at day 1.  Resource use data were collected on the following: 108 
consultations with health professionals, use of medications (over-the-counter and on 109 
prescription), medical investigations and hospital admissions.   110 
 111 
Unit costs 112 
Unit costs specific to each participating country were obtained mainly from national and 113 
international sources. In cases where costs were not available, they were obtained from a study 114 
previously published by the authors.21 These costs were inflated to 2016 prices using the 115 
consumer price index for each country.22 Where unit costs were unavailable, a market basket 116 
approach23 was used to estimate a relationship between the UK and the country of interest to 117 
obtain this cost. The UK was chosen because all unit costs were available for this setting.  118 
Medications were classified into 13 different groups. As it was not feasible to obtain unit costs 119 
for each individual drug for each country, a cost was generated for each of the 13 groups by 120 
estimating an average price from a list of drugs within that group. Table 1 gives a summary of 121 
the various sources of unit costs.  122 
Intervention costs 123 
For CRP, capital costs were obtained from the manufacturer (Orion Diagnostica) who quoted 124 
an average cost of €1,200. This cost was then annuitized assuming that the machine has a 125 
lifespan of three years, at an interest rate of 3.5%, and a cost-per-patient estimated. The costs 126 
of the reagents used (€7.45 (£6) per patient) were obtained from the provider (Oxford 127 
Biosystems).  128 
With respect to the communication skills, the cost of the booklet given to patients, €0.36 129 
(£0.29), was obtained from study coordinators and converted to country equivalent costs using 130 
the market basket approach.23 For the combined intervention, the cost of the CRP machine and 131 
the cost of booklet estimated above were included. 132 
To estimate the cost of the internet-based training, we obtained information on the amount of 133 
time GPs spent on it in each arm and estimated the total cost of time spent on training. This 134 
value was divided by the number of patients per GP to estimate the cost per patient. GPs spent 135 
on average 26.54 minutes, 37.44 minutes and 39.76 minutes on training in the CRP, 136 
communication skills and combined intervention arms respectively. Information on training 137 
has been published in a previous study.4 GPs also received face-to-face training in using the 138 
CRP device and a similar approach to that described above was used to estimate a cost per 139 
patient in each arm. All costs were converted to Euros using purchasing power parities. In 140 
addition to presenting costs in Euros, costs were also presented in Pounds Sterling. All costs 141 
are presented in 2016 prices.   142 
Previous research has highlighted the importance of including the cost of antibiotic resistance 143 
in economic evaluations assessing interventions in this area.24-25 As a result of this, cost of 144 
resistance figures generated from a recent study25 were added to every antibiotic prescription 145 
irrespective of the trial arm. The inclusion of these costs was limited to the cost-utility analysis 146 
since the outcome for the cost-effectiveness analysis (percentage reduction in antibiotic 147 
prescribing) indirectly accounts for antibiotic resistance given the fact that antibiotic 148 
prescribing leads to antibiotic resistance.   149 
Health outcomes 150 
Health outcomes were measured using the three-level version of the EQ-5D questionnaire. This 151 
instrument comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and 152 
anxiety/depression, each with three levels: no problems, some problems and severe problems.26 153 
Patients were asked to complete the EQ-5D-3L questionnaire over the entire four week period 154 
(at day 1, and at the end of weeks 1, 2, 3 and 4), or until they felt better.  EQ-5D-3L index 155 
scores were generated using the European Harmonised Tariff 27 and have been validated for 156 
use in respiratory disease.28  157 
Antibiotic prescribing 158 
Physicians were asked to state whether they prescribed an antibiotic and this information was 159 
used to estimate the rate of antibiotic prescribing in each of the trial arms.   160 
Statistical analysis 161 
The economic evaluation comprised two main analyses: a cost-utility analysis (CUA; cost per 162 
QALY gained) and a cost-effectiveness analysis (CEA; cost per percentage reduction in 163 
antibiotic prescribing). Both were carried out on an intention to treat basis. For each participant 164 
included in the study, a QALY score over the 4-week period was estimated using the area under 165 
the curve approach.29 Total healthcare costs over the 4-week period were calculated by 166 
multiplying the resource items used by the respective unit cost and summing over all items. 167 
Missing costs and health outcomes were imputed using a multiple imputation methodology. 168 
The technique used was predictive mean matching and the imputation model included 25 169 
imputed datasets 30    170 
Multilevel modelling, recommended for the economic evaluation of cluster and multinational 171 
trials, was used for data analysis.31-32 Dependent variables included total cost, QALYs and 172 
antibiotic prescribing. The model controlled for day 1 EQ-5D, gender, age, smoking, sex, 173 
crepitations, wheeze, pulse rate higher than 100 beats per minute, temperature higher than 37.8 174 
degrees Celsius, respiratory rate, blood pressure and duration of cough. These variables were 175 
controlled for in order to adopt a similar approach to the clinical study. To explore country 176 
variation in the cost-effectiveness of the interventions, adjusted country-specific cost-177 
effectiveness estimates were also obtained using a Bayesian approach.33 Minimally informative 178 
prior distributions were placed on all model parameters.34 All analysis was carried out in 179 
STATA 12, Winbugs 14 and R statistical software. Model estimates of the difference in costs, 180 
QALYs and antibiotic prescribing were used to derive an incremental cost-per-QALY-gained 181 
and an incremental cost-per-percentage-reduction in antibiotic prescribing.  182 
For the CUA, we used the NICE recommended threshold of between £20,000 to £30,000 183 
(€24,655 to €36,928) per QALY to judge the cost-effectiveness of the interventions.35 184 
A ‘Within the table’ analysis was adopted to account for the factorial nature of the trial.36-37 185 
This method assumes that the interventions are not independent i.e. the costs and effects of 186 
communication skills are influenced by the inclusion of CRP testing and vice-versa. This 187 
approach, which considers each treatment option individually, was used for the base-case 188 
analysis. All interventions were ordered in terms of increasing cost, for costs, QALYs and 189 
percentage reduction in antibiotic prescribing for each treatment arm to be compared 190 
incrementally. The most cost-effective option was selected based on the principles of 191 
dominance (where an intervention is less costly and more effective than the appropriate 192 
comparator(s)) and extended (weak) dominance (where an intervention is ruled out if the 193 
Incremental cost-effectiveness ratio (ICER) is greater than that of a more effective 194 
intervention).38 In addition, all interventions were compared to usual care individually.  195 
Sensitivity analysis 196 
Sensitivity analysis had two main foci. First, the results were compared against country-197 
specific thresholds to determine whether the interventions are cost-effective. This analysis was 198 
limited to the CUA and of the five participating countries, only the UK has an explicit threshold 199 
(£20,000 (€24,655) to £30,000 (€36,928) per QALY gained.35 There is no explicit threshold in 200 
the Netherlands, Belgium, Spain and Poland. However, a value of  €20,000 per QALY gained 201 
is often used in the Netherlands,39 €35,000 per QALY gained has been used to inform decision 202 
making in Belgium40 and in Spain, it has been suggested that the threshold value should lie 203 
between €22000 and €25000 per QALY gained.41 These values were therefore used to 204 
represent cost-effectiveness thresholds in the countries mentioned. No threshold value was 205 
identified in Poland.  206 
Second, to further explore the impact of including the cost of resistance, sensitivity analysis 207 
focused on conducting the economic evaluation without accounting for the cost of antibiotic 208 
resistance. This analysis was limited to the CUA since the base case CUA included the cost of 209 
resistance. 210 
 211 
 212 
 213 
Results 214 
A total of 246 practices participated in the study and contributed 4264 participants across five 215 
European countries. The country contribution to sample size ranged from 318 (7.5%) in 216 
Belgium to 1419 (33.3%) in Poland (Table 1).  217 
Resource use and costs 218 
A breakdown of resource use items is presented in Table 2. Compared to the other 219 
interventions, visits to the GP and hospital admissions were lower in the usual care arm. Visits 220 
to the GP were highest in the CRP group, whilst visits to the nurse were highest in the 221 
communication skills group. As was expected, those in the CRP and combined intervention 222 
groups had more CRP tests performed. Approximately 59% of participants in the usual care 223 
arm had an antibiotic prescribed compared to approximately 34% in the combined intervention 224 
arm. Costs associated with resource use items are presented in Table 3. GP costs were highest 225 
in the CRP group whilst nurse costs were highest in the communication skills group. Costs 226 
associated with over-the-counter medication were highest in the usual care arm.  227 
Outcomes 228 
There was an improvement in health of participants over the 4-week period as shown by the 229 
EQ-5D scores. The scores at four weeks were higher than those at day 1 in all four treatment 230 
arms (Table 4). Overall, antibiotic prescribing was highest in the usual care group and lowest 231 
in the combined intervention group (Table 4).  232 
 233 
 234 
 235 
Cost-utility analysis 236 
The CUA results indicate that overall, communication skills is the most cost-effective 237 
intervention since it dominated all other interventions (Table 5). Compared to usual care, both 238 
communication skills and CRP were dominant whilst the combined intervention was 239 
dominated. Country-specific estimates showed that communication skills was the most cost-240 
effective intervention in Belgium, UK and Netherlands. CRP is only cost-effective in 241 
Netherlands if the threshold is above €27,000 (£21,903) per QALY gained. CRP is cost-242 
effective in Poland whilst usual care is cost-effective in Spain (Table 5 and Figures 1 and 2).  243 
Cost-effectiveness analysis 244 
With respect to the CEA (percentage reduction in antibiotic prescribing as an outcome), 245 
communication skills was associated with an ICER of €68.08 (£55.23) per percentage 246 
reduction in antibiotic prescribing when compared to usual care. The ICER for CRP compared 247 
to communication skills was €176.53 (£143.20) per percentage reduction in antibiotic 248 
prescribing and the ICER for the combined intervention compared to CRP was €338.89 249 
(£274.90) per percentage reduction in antibiotic prescribing (Table 6). Compared to usual care, 250 
ICERs ranged from €68.08 (£55.23) per percentage reduction in antibiotic prescribing with 251 
communication skills to €126.21 (£102.38) per percentage reduction in antibiotic prescribing 252 
with the combined intervention. Country-specific estimates show that CRP is the most cost-253 
effective intervention in Belgium. In the Netherlands, CRP is cost-effective if society is willing 254 
to pay around €72 (£58) per percentage reduction in antibiotic prescribing. On the other hand, 255 
communication skills is the most cost-effective in Poland, Spain and the UK (Table 6 and 256 
Figures S1 and S2).  257 
 258 
Sensitivity analysis 259 
In terms of comparing the results to country-specific cost-effectiveness thresholds, 260 
communication skills was cost-effective in Belgium, Netherlands and UK, CRP was cost-261 
effective in Poland and Usual care was cost-effective in Spain (Table S1).  262 
The results of the sensitivity analysis which excludes the cost of antibiotic resistance are 263 
presented in Table S2, Figure S3 and Figure S4, and they show that, overall, usual care is cost-264 
effective if the cost of antibiotic resistance is not accounted for. The country-specific estimates 265 
also show that, with the exception of Belgium where communication skills was cost-effective, 266 
usual care is the most cost-effective intervention in all other countries when the cost of 267 
antibiotic resistance is not included. 268 
 269 
Discussion 270 
Summary of main findings 271 
This study evaluated the cost-effectiveness of (i) training GPs in the use of CRP testing, (ii) 272 
training GPs in communication skills and (iii) training GPs in both CRP testing compared to 273 
usual care. In terms of cost-per-percentage reduction in antibiotic prescribing, overall, 274 
communication skills was the most cost-effective. Similarly, the CUA also showed that 275 
communication skills was the most cost-effective intervention. However, the country-specific 276 
estimates were not consistent across the CUA and the CEA. The only country where 277 
communication skills was cost-effective across both the CUA and CEA was the UK. Compared 278 
to usual care, both communication skills and CRP are cost-effective. Sensitivity analysis where 279 
the cost of resistance was not included in the CUA led to a scenario where usual care was the 280 
most cost-effective intervention overall.  281 
Strengths and limitations of the study 282 
There are several strengths to this study. First, the factorial nature of the study enabled the 283 
relative cost-effectiveness of four different interventions to be explored within the same trial. 284 
Second, this study utilized data from five different European countries and so the findings may 285 
be more generalisable than those obtained from previous studies conducted in single country 286 
settings. Third, the study presented country-specific cost-effectiveness estimates, and, fourth, 287 
this study explored the implications of accounting for antibiotic resistance in economic 288 
evaluations.  289 
There are also a number of limitations. First, this study is conducted alongside a multinational, 290 
cluster randomised, factorial controlled trial, which presents additional complexities with 291 
respect to the analysis of the data. The factorial nature has the effect of reducing the sample 292 
size for any of the interventions on its own and therefore increasing the degree of uncertainty 293 
in the economic data. In this study, randomisation took place at the cluster/practice level whilst 294 
health economics outcomes such as QALYs were measured at the level of the individual. 295 
However, this has been addressed using methods that account for the hierarchical nature of the 296 
data. Second, assumptions were required to estimate country-specific unit costs where these 297 
were not available. Third, with respect to the CUA, since there is no European wide cost-298 
effectiveness threshold, this study relied on the UK threshold to judge the cost-effectiveness of 299 
interventions. Other studies have also noted problems with regards to the choice of cost-300 
effectiveness threshold in a multinational setting.42 Cost-effectiveness thresholds used in the 301 
Netherlands and Spain are €20,000 and €24,000 per QALY gained respectively. Fourth, with 302 
respect to the CEA, there is no commonly accepted threshold at which achieving an amount of 303 
antibiotic prescribing would be considered cost-effective. It is therefore difficult to reach a 304 
conclusion about the cost-effectiveness of the interventions based on an accepted threshold for 305 
the analysis. This study did not assess the long-term cost-effectiveness of the interventions 306 
under consideration. As a result of this, any long-term issues such as change in practice over 307 
time was not assessed. Finally, the use of estimates of the costs of antibiotic resistance is 308 
problematic given the difficulty of making such estimates. 309 
 310 
Comparison with other studies 311 
Other studies have reached similar conclusions about the cost-effectiveness of communication 312 
skills20 and CRP.20,43 This study therefore adds to the evidence about the potential benefits of 313 
CRP and communication skills, but for the first time in a rigorous experimental multinational 314 
context where the interventions have been assessed across a number of European countries. 315 
One previous study also concluded that ignoring the cost of antibiotic resistance in economic 316 
evaluations could lead to misleading conclusions,25 a result which is similar to what was found 317 
in this study.  318 
  319 
Policy implications and implications for future research 320 
The results of this study indicate that communication skills is cost-effective in terms of 321 
reducing antibiotic prescribing, and the intervention may offer a cost-effective way of 322 
preserving the effectiveness of the available antibiotics in an era where pharmaceutical 323 
companies are not successfully channelling enough resources into their development.2 Training 324 
GPs in advanced, relevant communication skills might also help to preserve the effectiveness 325 
of new antibiotics if and when they become available. Prescribing antibiotics to patients who 326 
are likely to benefit is one of the aims of the UK government’s five-year strategy on 327 
antibiotics44 and the widespread use of advanced, specific communication skills is likely to 328 
help achieve this aim since the intervention is both effective and cost-effective in terms of 329 
reducing antibiotic prescribing.  330 
Compared to usual care, CRP was also found to be cost-effective. Thus, CRP represents a more 331 
cost-effective means of reducing unnecessary antibiotic prescribing compared to usual care. 332 
However, this was not as cost-effective as communication skills. The National Institute for 333 
Health and Care Excellence (NICE) in the UK and Nederlands Huisartsen Genootschap (NHG) 334 
in the Netherlands have recommended that point of care CRP testing should be considered for 335 
patients presenting with symptoms of LRTI if it is not clear whether antibiotics should be 336 
prescribed.45-46 Similarly, Belgium has implemented training in communication skills at the 337 
national level. However, if governments and policy makers choose to adopt these interventions, 338 
the current cost of implementing them on a large scale needs to be considered.  The other issue 339 
that needs to be considered is whether the widespread use of testing will ‘medicalise’ largely 340 
self-limiting illnesses – by creating the perception that consulting for a test is necessary to 341 
decide whether treatment is necessary -  and thus increase consultations, potentially reducing 342 
efficiency and limiting the ability to reduce antibiotic prescribing.47 343 
The interventions considered in this study (communication skills and CRP) are primarily aimed 344 
at reducing the prescription of antibiotics by GPs and a potential question is whether the 345 
QALY, which is focused primarily on measuring health gain, should be the main outcome 346 
measure for interventions of this type. Whilst withholding antibiotics may lead to a reduction 347 
in health in the short-run,20 this may be considered acceptable in the context of prescribing 348 
antibiotics for future use, with the subsequent future health gain for the individual and society 349 
that implies. It is therefore suggested that the impact of antibiotic resistance should be 350 
accounted for in all economic evaluations of interventions that consider antibiotic use. Our 351 
study attempted to account for this by including a cost of resistance in the analysis and this 352 
clearly had a significant impact on the results that we obtained. The implication of not 353 
accounting for resistance is that policy makers may be led to believe that such an intervention 354 
may not provide value for money and not implement interventions that do not appear cost-355 
effective because the resistance costs are excluded. However, there are clear benefits to society 356 
when antibiotic prescribing is reduced. This study recommends that future research should 357 
focus on how to capture and include the cost of resistance in economic evaluations.   358 
In conclusion, internet-based training in communication skills is a cost-effective intervention 359 
to reduce antibiotic prescribing for respiratory tract infections in primary care if the cost of 360 
antibiotic resistance is accounted for.    361 
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TABLE 1: Source of valuation data and country contribution to sample size 
 Belgium Netherlands Poland Spain UK 
GP  Visits 1 1 1 1 2 
Nurse Visits N/A 1 1 1 2 
Out of hours GP 9 9 9 9 2 
Walk in centre N/A 1 1 1 1 
Hospital Admissions 1 1 1 1 8 
Investigations 9 9 9 9 8 
Medication 6 5 1,9 3,1 4 
Contribution to sample size 318 (7.5%) 329 (7.7%) 1419 (33.3%) 1318 (30.9%) 880 (20.6%) 
 
1= Previous study, 2= Curtis L (www.pssru.ac.uk), 3= www.vademecum.es, 4= British National Formulary (www.bnf.org), 5= Dutch healthcare 
insurance board (www.medicijnkosten.nl), 6= www.bcfi.be, 7= www.http://riziv.fgov.be, 8= NHS Reference costs 9= Market basket approach  
 
 
 
 
 
TABLE 2: Mean (SD) Resource use for complete case analysis 
 Usual care (n=515) CRP no Comm (n=660) Comm no CRP (n=740) CRP comm  
(n=709) 
PRIMARY CARE VISITS [Mean (SD)] 
GP visits 0.194 (0.472) 0.355 (0.762) 0.284 (0.713) 0.236 (0.596) 
Nurse Visits 0.016 (0.206) 0.045 (0.323) 0.103 (0.741) 0.039 (0.263) 
Out hours GP visits 0.015 (0.271) 0.006 (0.095) 0.023 (0.182) 0.016 (0.163) 
SECONDARY CARE VISTIS [Mean (SD)] 
Hospital emergency visits 0.002 (0.044) 0.003 (0.054) 0.018 (0.134) 0.016 (0.155) 
Walk in centre visits 0.004 (0.087) 0.002(0.039) 0.022 (0.186) 0.035 (0.383) 
Specialist visits 0.004 (0.062) 0.018 (0.155) 0.028 (0.222) 0.023 (0.218) 
Admissions 0.010 (0.182) 0.026 (0.379) 0.019 (0.320) 0.030 (0.394) 
PRESCRIPTIONS n (%) 
Antibiotic prescription 307 (59.61%) 222 (33.64%) 303 (40.95%) 242 (34.13%) 
Over the counter medication 346 (67.18%) 419 (63.48%) 451 (60.95%) 441 (62.20%) 
CRP test 12 (2.33%) 441 (66.82%) 57 (7.70%) 461 (65.02%) 
 
 
 
 
 
 
 
 
 
 
TABLE 3: Costs (Complete case analysis) (€) 
 Usual care (n=515) CRP no Comm (n=660) Comm no CRP (n=740) CRP comm  
(n=709) 
PRIMARY CARE VISITS 
GP visits €3.44 (10.27) €4.68 (11.23) €4.60 (13.90) €3.65 (10.12) 
Nurse Visits €0.22 (3.12) €0.32 (3.01) €1.36 (9.95) €0.49 (4.71) 
Out hours GP visits €5.30 (92.83) €2.04 (32.27) €8.07 (63.65) €5.36 (56.01) 
SECONDARY CARE VISTIS 
Hospital emergency visits €0.27 (6.22) €0.41 (7.48) €2.60 (18.73) €2.16 (21.30) 
Walk in centre visits €0.09 (2.03) €0.03 (0.90) €0.52 (4.52) €0.78 (7.90) 
Specialist visits €0.84 (13.54) €3.75 (31.70) €5.58 (44.60) €4.83 (46.70) 
Admissions €4.78 (89.56) €12.20 (179.20) €9.08 (150.58) €13.92 (186.81) 
OTHER COSTS 
Prescription €11.96 (26.87) €8.74 (19.32) €9.79 (19.04) €11.99 (34.64) 
OTC medication €6.55 (17.36) €4.48 (12.95) €4.52 (12.65) €6.18 (17.32) 
CRP test €0.19 (1.23) €5.24 (3.74) €0.28 (1.07) €4.88 (3.79) 
Trial intervention costa €0 €11.42 (7.45) €5.62 (3.69) €13.43 (8.53) 
Resistance cost €105.39 (94.01) €57.29 (84.86) €66.09 (84.49) €60.34 (88.02) 
 
a Cost associated with delivering the trial interventions  
 
 
 
 
 
 
 
TABLE 4: Mean EQ-5D scores over 4 weeks and antibiotic prescribing (Complete cases) 
 Usual care (n=515) CRP no Comm (n=660) Comm no CRP (n=740) CRP comm  
(n=709) 
EQ-5D 
Day 1 0.717 (0.216) 0.729 (0.212) 0.693 (0.228) 0.710 (0.223) 
Week 1 0.816 (0.197) 0.817 (0.207) 0.786 (0.214) 0.792 (0.210) 
Week 2 0.884 (0.176) 0.881 (0.182) 0.864 (0.185) 0.869 (0.186) 
Week 3 0.898 (0.170) 0.899 (0.176) 0.894 (0.176) 0.893 (0.174) 
Week 4 0.906 (0.165) 0.907 (0.169) 0.903 (0.168) 0.899 (0.169) 
Antibiotic prescribing 
Antibiotic Prescribing  0.596 (0.491) 0.336 (0.473) 0.409 (0.492) 0.341 (0.474) 
 
 
TABLE 5: Overall and country-specific cost-effectiveness (Cost-utility analysis) 
     
 Costa QALY ICER ICER (compared 
to UC) 
Overall (n=4264) 
CRP&Comm 94.36 0.0648 Dominated by Comm Dominated by UC 
Usual care 92.46 0.065 Dominated by Comm N/Af 
CRP 87.41 0.0651 Dominated by Comm Dominates UC 
Comm 83.21 0.0651 N/Af Dominates UC 
     
Belgium (n=318) 
Comm 93.28 0.0651 3450e 7120b 
CRP&comm 92.59 0.0649 7343c 8038b 
CRP 87.45 0.0642 12900b 12900b 
Usual care 86.16 0.0641 N/Af N/Af 
     
Netherlands (n=329) 
CRP&Comm 84.99 0.0649 Dominated by CRP Dominated by UC 
Usual care 75.52 0.065 Dominated by CRP N/Af 
CRP 73.41 0.0656 27,186c Dominates UC 
Comm 54.38 0.0649 N/Af N/A 
     
Poland (n=1419) 
Usual care 143.41 0.0663 49129c N/Af 
Comm 114.37 0.0656 Dominated by CRP 41486g 
CRP&Comm 110.95 0.0652 Dominated by CRP 29509g 
CRP 109.02 0.0656 N/Af 49129g 
     
Spain (n=1318) 
CRP&Comm 78.71 0.0648 Dominated by Usual care Dominated by UC 
CRP 70.86 0.0656 Dominated by Usual care Dominated by UC 
Usual care 66.46 0.0659 1000d N/Af 
Comm 65.86 0.0653 N/Af 1000g 
     
UK (n=880) 
CRP&Comm 106.57 0.0641 Dominated by Comm 25050b 
Usual care 101.56 0.0639 Dominated by Comm N/Af 
CRP 98.75 0.0645 Dominated by Comm Dominates UC 
Comm 98.05 0.0648 N/Af Dominates UC 
     
a Costs includes the costs associated with antibiotic resistance b Compared to usual care    c Compared 
to CRP training d Compared to communication skills training e Compared to training in both CRP 
testing and communication skills f not applicable, this is the  reference case           g ICER value 
represents a comparison of usual care versus the respective intervention since the ICER generated 
from a comparison of the respective intervention with usual care represents a willingness to accept a 
loss in benefit, rather than a willingness to pay for a gain in benefit.   UC=usual care
TABLE 6: Overall and country-specific cost-effectiveness (Cost-effectiveness analysis) 
 
Costa Outcome ICER 
ICER (compared 
to UC) 
Overall (n=4264) 
CRP + Comm 60.32 0.8003 338.8889b 126.209b 
CRP 49.34 0.7679 176.5343d 95.44643b 
Comm 39.56 0.7125 68.8019b 68.8019b 
Usual care 27.96 0.5439 N/Af N/A
f 
     
Belgium (n=318) 
CRP + Comm 62 0.8216 323.4528b 234.3308b 
CRP 52.07 0.7909 26.85393d 203.7946b 
Comm 49.68 0.7019 26350b 26350b 
Usual care 33.81 0.7013 N/Af N/A
f 
     
Netherlands (n=329) 
CRP + Comm 58.47 0.8409 1929.73c 126.6091b 
CRP 44.19 0.8335 72.67583b 72.67583b 
Usual care 26.21 0.5861 Dominated by Comm N/A
f 
Comm 26 0.7894 N/Af Dominates UC 
     
Poland (n=1419) 
CRP + Comm 61.3 0.7366 189.8754c 81.94658b 
CRP 49.11 0.6724 92.14953d 55.44933b 
Comm 44.18 0.6189 46.00962b 46.00962b 
Usual care 34.61 0.4109 N/Af N/A
f 
     
Spain (n=1318) 
CRP + Comm 47.5 0.8044 Dominated by CRP 162.4065b 
CRP 39.53 0.8156 145.0094d 100.5685b 
Comm 31.83 0.7625 78.13688b 78.13688b 
Usual care 23.61 0.6573 N/Af N/A
f 
     
UK (n=880) 
CRP + Comm 74.46 0.8066 202.439c 112.511b 
CRP 59.52 0.7328 170.1754d 95.16466b 
Comm 49.82 0.6758 82.03317b 82.03317b 
Usual care 23.11 0.3502 N/Af N/A
f 
     
a Costs excludes the costs associated with antibiotic resistance b Compared to usual care    c Compared 
to CRP training d Compared to communication skills training e Compared to training in both CRP 
testing and communication skills f not applicable, this is the reference case UC=usual care
Figure 1: Cost-effectiveness plane (cost-utility analysis) 
 
Figure 2: Cost-effectiveness acceptability frontier (cost-utility analysis) 
 
  
 
 
 
 
